Global High Content Screening Market is anticipated to expand at a 5.8% CAGR, reaching US$ 3 billion by 2033: FMI

The high content screening market is expanding due to increased demand for advanced cellular analysis and drug discovery tools.

FMI Logo

NEWARK, DELAWARE, UNITED STATES OF AMERICA, October 11, 2023 /EINPresswire.com/ -- The high-content screening market is predicted to grow positively, with a total estimated value expected to surpass US$ 3 billion by 2023. A 5.8% predicted compound annual growth rate (CAGR) in terms of sales volume (units) suggests that demand for high content screenings will soar.

Cellomics and high content screening (HCS) are related terms. It is a technique used in biological research and drug discovery to find new drug candidates. Digital microscopy and flow cytometry are the main foundations of high content screening systems, along with a combination of IT systems for the storage and analysis of biological data.

Request a Sample copy of this Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-426

The pharmaceutical industry has found that high content screening techniques are very effective for characterizing preclinical drugs. This technology frequently coexists with a variety of other uses, like drug development. The use of HCS in conjunction with chemical genetics to study biological systems is expected to grow over the next few years.

Key Takeaways:

The CAGR for the global market over the preceding period was 5.1%.

Over the coming decades, the market in India is anticipated to grow at a CAGR of 6.6%.

With more than 7.3% of all demand recorded in Europe in 2022, Germany has emerged as a major market.

Over the coming decade, the market in China is anticipated to grow at a CAGR of 7.8%.

The highest demand for High Content Screenings came from the pharmaceutical and healthcare industries.

“The rising prevalence of multiple infectious diseases with a variety of symptoms raises the demand for innovative treatments. As a result, there will be an increase in biotechnology and pharmaceutical study and development efforts to identify new drug candidates. Imaging technologies are becoming increasingly important in drug discovery and analysis,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

Competitive Landscape:

Key players in the HCS market employ strategies such as mergers and acquisitions, product launches, collaborations, and alliances to expand their businesses.

Particle Works, a progressive company that creates and markets cutting-edge particle engineering platforms, declared the release of the Automated Library Synthesis (ALiS) System, a new ground-breaking platform, in November 2022. This innovative platform favors automation in the early stages of the creation of drugs as well as high-throughput evaluation of lipid nanoparticle (LNP) formulations and mRNA candidates.

The Twist High Throughput Antibody Production platform, developed by California-based Twist Bioscience Corporation, was made public in April 2022. It allows customers to convert candidate genetic sequences into cleansed antibodies for use in a variety of applications related to screening and therapeutic discovery projects.

Key Companies:

Thermo Fisher Scientific Inc.
Becton Dickinson, and Company
GE Healthcare
Olympus Corporation
PerkinElmer Inc.
Sysmex Corporation
Merck KGaA
Danaher Corporation
Yokogawa Electric Corporation
BioTek Instruments Inc.

High Content Screening Market Segmentation:

Product Type:

Cell Imaging & Analysis
HCS Instruments
High-End HCS
Mid End HCS
Low-End HCS
Flow Cytometers
Consumables
Microplates
Reagents & Assay Kits
Other Consumables
Software
Services

Industry:

Pharmaceutical & Healthcare
Biotechnology
Educational Institutions
Independent CRO
Government Organizations
Others

Application:

Primary & Secondary Screening
Target Identification & Validation
Toxicity Studies
Compound Profiling
Others

Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of Health, ITN Online, and Spinal Surgery News.

Explore Extensive Coverage in Healthcare Market Domain:

Drug Discovery Enzymes Market Analysis: The market is likely to be worth US$ 1,751.3 million by 2033, from its projected value of US$ 932.4 million in 2023. A 6.5% CAGR in the market is predicted during the forecast period.

Drug Discovery Services Market Trends: It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to exhibit a captivating CAGR of 14.5% from 2023 to 2033.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube
